We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.04 | 0.14% | 28.42 | 1,310 | 09:20:36 |
From May 2019 to May 2024
By JOSH BECKERMAN
Pfizer Inc. said it will continue repurchasing stock with a new $11 billion buyback plan.
The drug company, which has a market capitalization of about $181 billion, said about $1.3 billion remained authorized under a prior buyback program.
Citing its strong operating cash flow, Pfizer said earlier in 2014 that it planned to buy about $5 billion of its shares this year.
Pfizer shares rose 1.4% to $29 in late trading Thursday.
In July, Pfizer said its second-quarter revenue fell 2%, hurt by foreign-currency changes and the expiration of its co-promotion with Amgen Inc. of Enbrel, a psoriasis and rheumatoid arthritis drug. The company lowered its revenue outlook for the year, pointing to the looming generic competition for painkiller Celebrex in December.
Pfizer dropped a $120 billion bid for AstraZeneca earlier this year. Pfizer Chief Executive Ian Read said in July that the company continues to evaluate other deals.
Write to Josh Beckerman at josh.beckerman@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
